IFNA1 and systemic lupus erythematosus: Overall, the use of peripheral blood IFN signatures as biomarkers is restricted to the diagnosis of interferonopathies and to clinical trials as IFN signatures did not recapitulate all SLE patients and a bias exists according to the ancestry [56,57].